Feiba VH market outlook improves as hemophilia demand rises

The Business Research Company says the global Feiba VH market is expanding as more hemophilia patients are diagnosed, surgical volumes rise and healthcare spending increases. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Feiba VH is used to control bleeding in hemophilia patients with inhibitors, a group that cannot rely fully on standard factor replacement therapy. - Rising diagnosis rates, more surgeries and broader healthcare spending are increasing demand for bypassing agents and related hemophilia treatments. - The market outlook matters for hospitals, specialty hemophilia centers and patients who need faster bleeding control and safer surgical care.

What happened: - The Business Research Company released a Feiba VH market report covering market size, trends and a global forecast for 2026-2035. - The report says the Feiba VH market has shown steady growth in recent years and is expected to keep expanding from 2026 to 2030. - The report identifies North America as the largest regional market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period. - A free sample of the report is available online. - A full market report is also available.

The details: - Feiba VH, also called anti-inhibitor coagulant complex, is designed to help hemophilia patients who develop antibodies that interfere with standard clotting factor treatments. - The therapy works by bypassing the impaired clotting pathway and supporting blood clotting during bleeding episodes. - The report links past market growth to limited success of standard factor replacement therapy in inhibitor patients, more hemophilia diagnoses, long clinical use of bypassing agents, continued hospital reliance on plasma-derived treatments and improved survival rates. - The report says future growth will be supported by personalized hemophilia care, wider access to specialized hemophilia centers, more inhibitor testing, better treatment adherence and stronger healthcare infrastructure. - Expected trends include greater use of bypassing agents, more inhibitor-positive hemophilia cases, preference for therapies that rapidly control bleeding, growth in home-based hemophilia care and improved emergency bleeding management. - The report says rising hemophilia prevalence is a core driver of demand. - Pfizer reported in April 2025 that the UK hemophilia A and B patient population exceeded 11,800 in 2023/24. - The report says rising surgical procedures are also boosting demand because hemophilia patients with inhibitors need careful bleeding control during operations. - The Australian Institute of Health and Welfare reported in May 2025 that public hospitals admitted 778,500 elective surgery patients in 2023-24, up 5.8% from the prior year. - The report says higher healthcare spending is helping expand access to advanced treatments such as Feiba VH. - The Canadian Institute for Health Information projected in November 2023 that Canada’s total health spending would reach $344 billion in 2023, or $8,740 per person, up 2.8% from the previous year. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market is being shaped less by a single product cycle and more by structural demand: more diagnoses, more procedures and stronger clinical infrastructure. - Home-based care and faster bleeding control point to a shift toward more flexible treatment delivery, especially for patients who need urgent management outside major hospitals. - The regional split suggests mature markets still dominate revenue, while emerging markets are gaining ground as access and awareness improve.

What’s next: - Demand is likely to rise as inhibitor testing expands and more patients move into specialized hemophilia care. - The market could benefit from continued investment in healthcare systems, reimbursement coverage and emergency bleeding protocols. - The report’s 2026-2030 forecast window points to sustained growth rather than a short-term spike.

The bottom line: - Feiba VH is moving from a niche inhibitor-treatment option toward a stronger growth market as hemophilia diagnosis, surgery volume and healthcare access continue to climb.